Plain-English translation of NCT07289464 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage safety study of RSS0343, a new oral medication being developed to treat a lung condition called non-cystic fibrosis bronchiectasis. Researchers want to understand how the medication works in the body, whether it's safe to take multiple doses, and whether it affects the heart's electrical activity. The study will enroll 48 healthy volunteers.
Before this medication can be tested in patients with lung disease, researchers need to make sure it's safe and doesn't cause serious side effects in healthy people first. This trial is an important first step to gather safety information.
You likely qualify if…
You likely don't qualify if…
You will take either the new medication or a placebo (a dummy pill with no active ingredient) by mouth multiple times during the study. You'll have several clinic visits where the research team will check your vital signs, draw blood samples, perform heart tests, and monitor you for any side effects. The study will track how your body processes the medication and watch for any effects on your heart's electrical rhythm.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Reistone Biopharma Company Limited
Enrollment target
~48 participants
Started
January 2026
Primary completion
September 2026
Age range
18 Years – 55 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ye Xu
Reistone Biopharma Company Limited
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.